About Mauna Kea Tech
Mauna Kea Tech is a company based in Paris (France) founded in 2000. Mauna Kea Tech has raised $30 million across 7 funding rounds from investors including European Investment Bank, European Union and Telix Pharmaceuticals. The company has 54 employees as of December 31, 2024. Mauna Kea Tech offers products and services including Cellvizio Platform and Confocal Miniprobes. Mauna Kea Tech operates in a competitive market with competitors including EchoSens, CapsoVision, Smart Medical Systems, Invendo Medical and GI View, among others.
- Headquarter Paris, France
- Employees 54 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mauna Kea Technologies Sa Class O
-
Annual Revenue
$7.96 M (USD)-26.96as on Dec 31, 2024
-
Net Profit
-$10.8 M (USD)-179.15as on Dec 31, 2024
-
EBITDA
-$5.23 M (USD)-11.33as on Dec 31, 2024
-
Total Equity Funding
$30 M (USD)
in 7 rounds
-
Latest Funding Round
$6.41 M (USD), Post-IPO
Nov 13, 2023
-
Investors
European Investment Bank
& 6 more
-
Employee Count
54
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mauna Kea Tech
Mauna Kea Tech is a publicly listed company on the EURONEXT with ticker symbol ALMKT in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mauna Kea Tech
Mauna Kea Tech offers a comprehensive portfolio of products and services, including Cellvizio Platform and Confocal Miniprobes.
Offers real-time in vivo cellular imaging for disease diagnosis and treatment.
Tools for inserting into endoscopes to enable cellular visualization.
People of Mauna Kea Tech
Unlock access to complete
Unlock access to complete
Funding Insights of Mauna Kea Tech
Mauna Kea Tech has successfully raised a total of $30M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.41 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $6.4M
-
First Round
First Round
(23 Jan 2008)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Post-IPO - Mauna Kea Tech | Valuation |
investors |
|
| Dec, 2019 | Amount | Post-IPO - Mauna Kea Tech | Valuation |
investors |
|
| Jul, 2019 | Amount | Debt – Conventional - Mauna Kea Tech | Valuation |
investors |
Investors in Mauna Kea Tech
Mauna Kea Tech has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include European Investment Bank, European Union and Telix Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Founded Year | Domain | Location | |
|
Alternative financing is provided by IPF Partners for healthcare.
|
Founded Year | Domain | Location | |
|
Tech and offline sectors are invested in globally by Creadev.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mauna Kea Tech
Financial Statements - Mauna Kea Tech
Mauna Kea Tech Comparisons
Competitors of Mauna Kea Tech
Mauna Kea Tech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EchoSens, CapsoVision, Smart Medical Systems, Invendo Medical and GI View, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-invasive diagnostics for liver disease detection are developed.
|
|
| domain | founded_year | HQ Location |
GI capsule endoscopy systems are developed for intestinal imaging.
|
|
| domain | founded_year | HQ Location |
Endoscopes and devices for GI diagnosis and treatment are produced.
|
|
| domain | founded_year | HQ Location |
Sterile single-use robotics-based endoscopes are developed for gastroenterology.
|
|
| domain | founded_year | HQ Location |
Devices for GI disorder diagnosis and treatment are developed.
|
Latest news on Mauna Kea Tech
Frequently Asked Questions about Mauna Kea Tech
Mauna Kea Tech was founded in 2000 and raised its 1st funding round 8 years after it was founded.
Mauna Kea Tech is headquartered in Paris, France.
Mauna Kea Tech is a funded company, having raised a total of $30M across 7 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $12.89M, raised on Jan 23, 2008.
As of Dec 31, 2024, the latest employee count at Mauna Kea Tech is 54.
Annual revenue of Mauna Kea Tech is $7.96M as on Dec 31, 2024.
Mauna Kea Technologies produces devices for microscopic imaging during endoscopy procedures. Its tools allow surgeons to visualize, take biopsies, detect or rule out malignant or pre-malignant tumors or lesions in the gastrointestinal tract and pulmonary tracts. Their flagship product, Cellvizio, is a probe-based Confocal Laser Endomicroscopy (pCLE) system, that provides real-time access to histological images during standard endoscopy procedures through high-resolution cellular imaging of internal tissues. Cellvizio is cleared by FDA and has the European CE-Mark for use during digestive, pulmonary and urinary endoscopy procedures, including pancreatic and biliary endoscopic explorations as well as fine needle aspiration procedures. Mauna Kea Technologies also obtained clearance in China and Japan. Cellvizio went public in July 2011 and trades on the NYSE Euronext exchange.
Mauna Kea Tech's top competitors include EchoSens, CapsoVision and Invendo Medical.
Mauna Kea Tech offers Cellvizio Platform and Confocal Miniprobes.
Yes, Mauna Kea Tech is publicly traded on EURONEXT under the ticker symbol ALMKT.
Mauna Kea Tech has 7 investors. Key investors include European Investment Bank, European Union, Telix Pharmaceuticals, Johnson & Johnson Innovation, and IPF Partners.
The ticker symbol of Mauna Kea Tech is ALMKT on EURONEXT.